Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Ndjeka

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|April 2, 2016
A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosisKathryn Schnippel, Norbert Ndjeka, Francesca Conradie, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|August 16, 2011
Prevalence of drug-resistant mutations in newly diagnosed drug-naïve HIV-1-infected individuals in a treatment site in the waterberg district, limpopo provinceJulius Nwobegahay, Pascal Bessong, Tracy Masebe, et al.
Plos One|April 8, 2020
Pre-treatment loss to follow-up among children with multidrug-resistant tuberculosis in South Africa, 2008-2010Brittany K Moore, Linda Erasmus, Julia Ershova, et al.
The Lancet. Respiratory Medicine|July 19, 2025
endTB-Q results in the face of rising bedaquiline resistanceNorbert Heinrich, Norbert Ndjeka, Celso Khosa, et al.
PLOS Global Public Health|May 6, 2024
Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomesKeri Geiger, Amita Patil, Chakra Budhathoki, et al.
Plos Medicine|February 22, 2017
Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort studyHelen Cox, Lindy Dickson-Hall, Norbert Ndjeka, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2023
Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed OpportunityKeri Geiger, Amita Patil, Chakra Budhathoki, et al.
Human Resources for Health|January 7, 2021
Preparing the healthcare workforce in South Africa for short-course rifampicin-resistant TB treatment: inter-professional training and task-sharing considerationsJason E Farley, Norbert Ndjeka, Khaya Mlandu, et al.
Emerging Infectious Diseases|January 11, 2020
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant TuberculosisJonathon R Campbell, Dennis Falzon, Fuad Mirzayev, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 25, 2024
Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort StudyHannah Morgan, Norbert Ndjeka, Tasnim Hasan, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|April 2, 2016
A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosisKathryn Schnippel, Norbert Ndjeka, Francesca Conradie, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|August 16, 2011
Prevalence of drug-resistant mutations in newly diagnosed drug-naïve HIV-1-infected individuals in a treatment site in the waterberg district, limpopo provinceJulius Nwobegahay, Pascal Bessong, Tracy Masebe, et al.
Plos One|April 8, 2020
Pre-treatment loss to follow-up among children with multidrug-resistant tuberculosis in South Africa, 2008-2010Brittany K Moore, Linda Erasmus, Julia Ershova, et al.
The Lancet. Respiratory Medicine|July 19, 2025
endTB-Q results in the face of rising bedaquiline resistanceNorbert Heinrich, Norbert Ndjeka, Celso Khosa, et al.
PLOS Global Public Health|May 6, 2024
Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomesKeri Geiger, Amita Patil, Chakra Budhathoki, et al.
Plos Medicine|February 22, 2017
Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort studyHelen Cox, Lindy Dickson-Hall, Norbert Ndjeka, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2023
Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed OpportunityKeri Geiger, Amita Patil, Chakra Budhathoki, et al.
Human Resources for Health|January 7, 2021
Preparing the healthcare workforce in South Africa for short-course rifampicin-resistant TB treatment: inter-professional training and task-sharing considerationsJason E Farley, Norbert Ndjeka, Khaya Mlandu, et al.
Emerging Infectious Diseases|January 11, 2020
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant TuberculosisJonathon R Campbell, Dennis Falzon, Fuad Mirzayev, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 25, 2024
Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort StudyHannah Morgan, Norbert Ndjeka, Tasnim Hasan, et al.
Pageof 6